The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance

Fundamental and Clinical Pharmacology

Volumn 21, Issue SUPPL. 2, 2007, Pages 21-26

  Catapano, Alberico L ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Intestine; LDL; Liver; NPC1L1

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ABC TRANSPORTER; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADD ON THERAPY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG MECHANISM; GENE EXPRESSION; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INTESTINE; INTESTINE ABSORPTION; LIVER; MOUSE STRAIN; NIEMANN PICK DISEASE; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AZETIDINES; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INTESTINAL ABSORPTION; LIVER;

EID: 36248957625     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2007.00534.x     Document Type: Review

References (33)

1. Steinberg D., Witztum J.L. Lipoproteins and atherogenesis. Current concepts. JAMA (1990) 264 3047 3052.
2. Castelli W.P., Anderson K, Wilson P.W., Levy D. Lipids and risk of coronary heart disease. The Framingham Study. Ann. Epidemiol. (1992) 2 23 28.
3. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA (1984) 251 351 364.
4. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New Engl. J. Med. (1995) 333 1301 1307.
5. Collins R., Armitage J., Parish S., Sleight P., Peto R. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet (2004) 363 757 767.
6. Downs J.R., Clearfield M., Tyroler H.A. et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am. J. Cardiol. (2001) 87 1074 1079.
7. Manninen V., Elo M.O., Frick M.H. et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 260 641 651.
8. Frick M.H., Elo O., Haapa K. et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. New Engl. J. Med. (1987) 317 1237 1245.
9. Goettsch W.G., Yin D.D., Alemao E., Klungel O.H., Stalenhoef A.F., Herings R.M. Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study. Curr. Med. Res. Opin. (2004) 20 1025 1033.
10. Foley K.A., Simpson R.J. Jr., Crouse J.R. III., Weiss T.W., Markson L.E., Alexander C.M. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol. (2003) 92 79 81.
11. Neal R.C., Jones P.H. Lipid-lowering: can ezetimibe help close the treatment gap? Cleve. Clin. J. Med. (2003) 70 777 783.
12. Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. (2004) 44 720 732.
13. Levy E, Spahis S, Sinnet D et al. Intestinal cholesterol transport proteins: an update and beyond. Curr. Opin. Lipidol. (2007) 18 310 318.
14. Goldstein J.L., Brown M.S. Regulation of mevalonate pathway. Nature (1990) 343 425 430.
15. Wang D.Q.H. Regulation of intestinal cholesterol absorbtion. Annu. Rev. Physiol. (2007) 69 221 248.
16. Lammert F., Wang D.Q.H. New insights into the genetic regulation of intestinal cholesterol absorbtion. Gastroenterology (2005) 129 718 734.
17. Cook R.P. Cholesterol. Distribution of sterols in organisms and in tissues, in : Cook R.P. (Ed Cholesterol. Chemistry, biochemistry, and pathology, Academic Press, Inc, New York, 1958, pp. 145 180.
18. Illingworth D.R., Duell P.B., Connor W.E. Disorders of lipid metabolism, in : Felig P., Baxter J.D., Frohman L.A. (Eds Endocrinology and metabolism, McGraw-Hill, New York, 1995, pp. 1315 1403.
19. Dietschy J.M., Turley S.D., Spady D.K. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid Res. (1993) 34 1637 1659.
20. Salen G., Tint G.S., Shefer S., Shore V., Nguyen L. Increased sitosterol absorption is offset by rapid elimination to prevent accumulation in heterozygotes with sitosterolemia. Arterioscler. Thromb. (1999) 12 563 568.
21. Davies J.P., Ioannou Y.A. Topological analysis of Niemann-Pick C1 protein reveals that the membrane orientation of the putative sterol-sensing domain is identical to those of 3-hydroxy-3-methylglutaryl-CoA reductase and sterol regulatory element binding protein cleavage-activating protein. J. Biol. Chem. (2000) 275 24367 24374.
22. Carstea E.D. et al. Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis. Science (1997) 277 228 231.
23. Altmann S.W., Davis H.R. Jr., Zhu L.J. et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science (2004) 303 1201 1204.
24. Russell D.W. Nuclear orphan receptors control cholesterol catabolism. Cell (1999) 97 539 542.
25. Repa J.J., Mangelsdorf D.J. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. (2002) 8 1243 1248.
26. Repa J.J., Turley S.D., Lobaccaro J.M.A. et al. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289 1524 1529.
27. Brewer H.B. Jr., Santamarina-Fojo S. New insights into the role of the adenosine triphosphate-binding cassette transporters in high-density lipoprotein metabolism and reverse cholesterol transport. Am. J. Cardiol. (2003) 91 3E 11E.
28. Seedorf U., Engel T., Lueken A., Bode G., Lorkowski S., Assmann G. Cholesterol absorption inhibitor ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem. Biophys. Res. Commun. (2004) 320 1337 1341.
29. Garcia-Calvo M. et al. The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA (2005) 102 8132 8137.
30. Patrick J.E., Kosoglou T., Stauber K.L. et al. Disposition of the selective cholesterol absorption randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 344 1383 1389.
31. Kosoglou T., Statkevich P., Johnson-Levonas A.O., Paolini J.F., Bergman A.J., Alton K.B. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. (2005) 44 67 94.
32. Parker R.A., Lark R.W., Sit S.Y., Lanier T.L., Grosso R.A., Wright J.J. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J. Lipid Res. (1990) 31 1271 1282.
33. Pearson T.A., Denke M.A., McBride P.E., Battisti W.P., Brady W.E., Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc. (2005) 80 587 595.